Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article outlines the author's personal strategies for managing dermatological toxicities, such as acneiform rash and dry skin, associated with EGFR inhibitor therapy; it does not present new research findings.

This study highlights lichen planopilaris as a form of scarring hair loss with symptoms like shedding and itching, and notes successful treatment options such as topical and oral antiinflammatory medications to preserve hair follicles by early intervention.

This study reports that progressive frontal fibrosing alopecia, a distinct and gradually stabilizing form of lichen planopilaris affecting elderly women and often involving eyebrow hair loss, lacks effective treatments.

These guidelines review the management of complications and specific forms of congenital ichthyosis and report no new results; they summarize expert and evidence-based recommendations for clinicians.

This review highlights that microneedling shows some promise for improving hair growth in alopecia, particularly when used with other treatments, though more research is needed to establish its efficacy and protocols.

This study found that 2% topical minoxidil solution was significantly more effective than placebo in promoting new hair growth in women with androgenetic alopecia.

This review highlights that idiopathic hirsutism is characterized by local hyperandrogenization affecting hair growth, without other signs of hyperandrogenism, and shows no new results; racial differences in prevalence are noted but not in androgenic steroids.

This study found that topical melatonin solution was associated with positive effects on hair density and reduction in hair loss for androgenetic alopecia, with good tolerability reported in several clinical trials.

The study concluded that poly(propylene carbonate maleate) microspheres effectively encapsulated finasteride, achieving a biphasic release with prolonged drug release over 5-6 weeks in vitro.

This study reported that the most common skin side effect of epidermal growth factor receptor inhibitors was a papulopustular rash, treatable with symptom-targeted therapies, while drug suspension was rarely needed.

This review discusses recent surgical and medical advancements in hair restoration techniques but reports no new clinical results.

This review explores factors affecting graft growth and survival in hair restoration, emphasizing the importance of fundamental care practices while considering advanced storage solutions and additives, but reports no new findings.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This review discusses the varied cutaneous manifestations of Systemic Lupus Erythematosus and outlines treatment approaches, but it reports no new clinical findings.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study evaluated treatments for frontal fibrosing alopecia and found hydroxychloroquine and 5a-reductase inhibitors to be most effective, with 70-72% of patients experiencing stabilization or improvement, but limitations in treatment consistency and assessment methods remain.

This study is the first to report that apremilast may be effective in treating refractory lichen planopilaris and frontal fibrosing alopecia, though some patients experienced adverse effects leading to discontinuation.

This study reviews current pharmacological treatments for alopecia, highlighting minoxidil, 5α-reductase inhibitors, JAK inhibitors, and other agents, and notes ongoing research aimed at improving their effectiveness and safety profiles.

In this study, researchers evaluated the stability and color changes of compounded minoxidil formulations used for alopecia, finding that while the formulations remained chemically and microbiologically stable for up to 380 days, significant color changes were observed, which likely do not affect the product's effectiveness.

This review found that antimalarial agents were more effective than steroids for Lichen planopilaris, while finasteride and dutasteride showed favorable impacts on frontal fibrosing alopecia, despite heterogeneous study quality.

This chapter reviews differences in dermatological treatments and conditions between male and female patients, particularly noting the impacts of sex steroids on various skin processes, but presents no new clinical findings.

This review discusses the incidence, demographics, and associated conditions of alopecia areata and provides no new clinical findings.

This case report describes a patient with systemic sclerosis and severe alopecia areata who experienced complete resolution of hair loss within four months after treatment with topical steroids, minoxidil, and mycophenolate mofetil.

This study found that polymers significantly improved the chemical and microbial stability of steroid hormones in liposome formulations over eight weeks, with finasteride showing the highest diffusion rate.

In this study, nandrolone decanoate treatment in rats caused persistent diestrus and altered steroid receptor expression and sex hormones, especially at higher doses, with partial reversibility at lower doses over time.

This study suggests that male sex and androgenic steroid use increase the risk of atrial arrhythmias in individuals with arrhythmogenic right ventricular cardiomyopathy, especially those with desmosomal gene mutations.

This chapter reviews the causes, prevalence, and prognosis of androgenetic alopecia and discusses treatments like topical minoxidil and systemic finasteride to stop hair loss and potentially increase hair density.

This study found that a 2% topical minoxidil solution significantly increased hair regrowth compared to placebo in women with androgenetic alopecia over 32 weeks.

This review discusses gender identity disorder in Japan, highlighting the high prevalence and challenges in accessing appropriate treatment, and calls for wider understanding among medical professionals.

This study evaluated the efficacy and safety of a 5% minoxidil topical foam without propylene glycol in men with androgenic alopecia.